HIGHLIGHTS
- who: Dzhangar Dzhumashev et al. from the Department of Pediatric Hematology and Oncology, Inselspital, Bern University Hospital, Bern, Switzerland have published the article: Quantum Dot-Based Screening Identifies F3 Peptide and Reveals Cell Surface Nucleolin as a Therapeutic Target for Rhabdomyosarcoma, in the Journal: Cancers 2022, 5048 of /2022/
- what: Based on the results , the authors propose a high and dynamic presence of nucleolin on the cell surface that makes it an attractive target for RMS treatment with proapoptotic ligands such as AS1411 and N6L, or with antibody-drug conjugates (ADC) based on high-affinity . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.